Recent Company News

• 05:09 PM ET Mar 09, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 04:04 PM ET Mar 09, 2026
  

  Xencor discloses notice of termination of collaboration and license agreement with Genentech/Roche - 8-K ($11.87, 0.00)

• 09:03 AM ET Mar 09, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 07:57 AM ET Mar 09, 2026
  

  Energy and defensives the best performers; airlines, industrials, real estate and resources the big laggards:

• 05:57 AM ET Mar 09, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 03:51 AM ET Mar 09, 2026
  

  StreetAccount Summary - European pre-market trading update

• 02:45 AM ET Mar 09, 2026
  

  European macro headlines:

• 02:03 AM ET Mar 09, 2026
  

  Roche announces phase III persevERA study in ER-positive advanced breast cancer did not meet its primary objective (CHF 341.20, 0.00)

• 01:56 AM ET Mar 09, 2026
  

  Roche CEO discusses the company's exposure to US tariffs in an interview with the NZZ (CHF 341.20, 0.00)

• 12:21 AM ET Mar 07, 2026
  

  StreetAccount Sector Summary - Healthcare Weekly Recap